Energy Efficient Freeze Drying Enhances Pharmaceutical Production
SP Scientific has produced a new technical brief that summarises the energy saving features available on its Hull range of production freeze drying systems.
Out of the many steps required to produce pharmaceuticals products, freeze drying is perhaps the most energy intensive of the various production processes. Most of the energy consumed by a freeze dryer goes into the refrigeration system which must initially freeze the product and heat transfer shelves, and then condense water vapour that sublimates and desorbs out of the product during primary and secondary drying respectively.
For the last 20 years, Hull production freeze dryers have been at the forefront of pioneering ever more efficient use of the energy required to drive the lyophilisation process. This new technical brief details these energy saving technical innovations and explains how they translate into energy/cost savings in pharmaceutical production.
Smart Cool 4.0 technology utilizes the inherent flexibility of electronic expansion valves to capture greater compressor capacity under heavy loads (such as fast cooling of product); at the same time, it allows precise shelf control within +/- 1 °C. The result is that a typical Hull freeze dryer can meet or exceed the performance of other production freeze dryers using fewer and/or smaller compressors, especially when combined with MultiFlex refrigeration.
Employing highly efficient heat transfer fluid cooled condensers, SP Scientific's proprietary MultiFlex refrigeration design enables Hull freeze dryers to meet process needs with fewer and/or smaller compressors, which results not only in significant energy savings, but overall reduced operational costs due to decreased maintenance requirements.
In addition, the document describes and explains the benefits of Screw Compressor technology, Variable Frequency Drives, Water Cooled Heat Exchangers and high efficiency liquid Nitrogen refrigeration systems.
To download a copy of this new technical brief, visit www.spscientific.com or for further information on energy efficient production scale freeze drying please contact SP Scientific’s Charles D. Dern, P.E. on +1 845 255 5000 or [email protected]
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance